Return to CG151 Overview

Neutropenic sepsis: prevention and management in people with cancer [CG151]

Measuring the use of this guidance

Recommendation: 1.4.3.1

Offer beta lactam monotherapy with piperacillin with tazobactam as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment unless there are patient-specific or local microbiological contraindications.

What was measured: Proportion of patients that received empirical first line antibiotics.
Data collection end: July 2013
80%
Number that met the criteria: 28 / 35
Area covered: Local
Source: Swan DR (2014) An audit of the effect of introduction of antibiotic monotherapy guidance on the management of febrile neutropenia, in a tertiary centre. British Journal of Haematology May: var.pagings


Recommendation: 1.4.4.1

Diagnose neutropenic sepsis in patients having anticancer treatment whose neutrophil count is 0.5×109 per litre or lower and who have either: • a temperature higher than 38oC or • other signs or symptoms consistent with clinically significant sepsis.

What was measured: Proportion of patients diagnosed with neutropenic sepsis using the diagnostic criteria defined by NICE.
Data collection end: July 2013
91.4%
Number that met the criteria: 32 / 35
Area covered: Local
Source: Swan DR (2014) An audit of the effect of introduction of antibiotic monotherapy guidance on the management of febrile neutropenia, in a tertiary centre. British Journal of Haematology May: var.pagings



 Return to CG151 Overview